Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research

The National Institute of Diabetes and Digestive and Kidney Diseases, a part of the U.S. Department of Health and Human Services, in collaboration with the National Heart, Lung, and Blood Institute, intends to continue advancing cardiovascular research in type 1 diabetes through the CARE-T1D consortium. This initiative began in 2024 with six research teams formed under RFA-DK-23-021 to explore the mechanisms of cardiac disease in type 1 diabetes using multi-omics and molecular methodologies. The new funding opportunity aims to build upon that foundation by sustaining and expanding the work of the consortium. The primary objective of this program is to support discovery and mechanistic research that deepens the understanding of cardiovascular disease in individuals with type 1 diabetes. Investigators will be encouraged to utilize the CARE-T1D repository and resources to conduct hypothesis-driven studies. Collaborative projects that integrate insights from related fields, such as type 2 diabetes, atherosclerosis, inflammation, and advanced omics techniques, will also be supported. The focus is on developing innovative approaches to unravel the pathogenesis of cardiovascular disease in type 1 diabetes and ultimately inform improved prevention and treatment strategies. This funding opportunity is structured as a cooperative agreement under the U01 mechanism, which indicates substantial programmatic involvement from the funding agency. The estimated total program funding is $4,500,000, with up to eight awards expected. While award ceiling and floor amounts are not specified, funds will be distributed to successful applicants based on merit and alignment with the objectives of the consortium. No cost-sharing or matching is required, making this opportunity more accessible to a wide range of institutions. Eligibility is broad, encompassing state, county, and tribal governments, school districts, higher education institutions, nonprofits, public housing authorities, small businesses, and other organizations. In addition, federally recognized and non-federally recognized tribal organizations, U.S. territories, foreign institutions, and faith-based or community-based organizations may also apply. Eligible federal agencies and regional organizations are permitted to participate as well. This wide eligibility reflects the program’s intent to attract diverse expertise and foster multidisciplinary collaboration. The forecasted opportunity outlines a projected application timeline. The estimated posting date is April 1, 2026, with applications due by July 1, 2026. Awards are expected to be announced by March 1, 2027, with projects beginning the same day. No pre-application requirements such as letters of intent or concept papers are identified at this stage. As a forecasted notice, details are subject to finalization upon the official release of the Notice of Funding Opportunity. Applicants seeking further clarification are directed to contact Chandima Nishadi De Abrew Rajapakse, PhD, MHS, at 240-429-5197 or via email at Chandima.rajapakse@nih.gov. This individual will serve as the primary contact for scientific and administrative inquiries. Interested applicants are encouraged to monitor Grants.gov and NIH communications for updates, as this notice represents an early stage of engagement and is not yet open for submission. With its emphasis on collaborative and mechanistic research, this program represents a significant opportunity for investigators dedicated to understanding and addressing cardiovascular disease in the context of type 1 diabetes.